Artivion Says $100,000 Upfront Cost Is Stalling AMDS Starter-Set Orders Even As Implants Rise
CEO Pat Mackin calls the purchase-order bottleneck administrative and transient, and the company narrowed 2026 growth guidance to 8% to 10%.
Artivion, which makes aortic stent grafts, mechanical heart valves, surgical sealants and human cardiac tissue for aortic disease, said hospitals are slow to pay the $100,000 starter set for its AMDS dissection device, CEO Pat Mackin told analysts on the company's third-quarter earnings call Thursday. He called the problem "administrative and transient," and the company narrowed its 2026 outlook to reported revenue of $484 million to $492 million.
A $100,000 purchase order
Hospitals have to buy four AMDS devices up front for $100,000, Mackin said. "It's proving, you know, more difficult than we probably expected at the beginning of this," he said.
He described the bottleneck as administrative, not clinical. Value analysis committees, the hospital panels that approve new products, are not the obstacle: "I don't think there's any VAC that we've not gotten through," Mackin said, calling the purchase order "the new piece." Artivion chose not to put consignment inventory in hospitals, he said, because the technology is unique and life-saving, and the purchase requirement has become a challenge in what he called bureaucratic hospital systems.
A Jefferies analyst asked what is not resonating. Mackin pointed to hospitals' lack of awareness of DRG 209, a reimbursement increase for complex arch work that covers AMDS and took effect in October last year.
Implants up, sets lagging
U.S. AMDS implants rose from the second quarter, which Mackin tied to the recent PMA approval, the FDA's full marketing clearance. He said the approval did nothing for the purchase-order burden.
Mackin estimated about 800 U.S. centers perform acute type A dissection repairs, 300 to 400 of them high-volume. He expects to keep opening new starter sets for the next couple of years.
Third-quarter revenue was $123.8 million, up 9% in constant currency. Stent graft revenue rose 12%, and free cash flow was negative $17.6 million. CFO Lance Berry said $13.3 million of the AMDS PMA milestone payment had to be classified as operating cash, along with about $2 million of Endospan integration costs.
Guidance and the next dates
Berry said adjusted constant-currency growth for 2026 is now 8% to 10%, and adjusted EBITDA is $93 million to $98 million. For 2027, he said analysts should take two percentage points off revenue growth and four off EBITDA growth because the Baxter per-clot supply agreement is ending.
Nexus, the aortic arch device, is slated for U.S. launch in January 2027. Unlike AMDS, Mackin said, it needs no upfront purchase.
Artivion's first 30 ARTISAN trial patients will be presented at an aortic symposium on Thursday, November 19, he said.
The company reports again in February, Mackin said.
Sources
- Artivion outlines 2026 revenue of $484M to $492M while preparing January 2027 NEXUS launch (NYSE:AORT) | Seeking Alpha — seekingalpha.com
- Artivion (AORT) Lags Q3 Earnings Estimates — Yahoo Finance
- Artivion Non-GAAP EPS of $0.08 beats by $0.01, revenue of $123.8M beats by $2.83M (AORT:NYSE) | Seeking Alpha — seekingalpha.com
- Artivion: Q3 Earnings Snapshot – WTOP News — wtop.com
- Artivion: Q3 Earnings Snapshot | khou.com — Associated Press